linjc16/ctgov huggingface dataset:
To Establish the Traditional Chinese Medicine Based Intelligent Personal Health Care System

Study Overview
=================
Brief Summary
-----------------
Development of a New Generation Chinese Medicine Constitution Assessment Scale

Detailed Description
-----------------
Development of a New Generation Chinese Medicine Constitution Assessment Scale: A. Analyzing the existing CCMQ and BCQ questionnaire syntax. B. Redesigning the scale's question statements. C. Reintegrating the scale items and constitutional characteristics. D. Testing and evaluating the reliability and validity of the questionnaire, cross-assessing with diagnoses from experienced Chinese medicine practitioners. E. Collecting feedback and reviewing modifications based on the responses from the general population questionnaire.

Official Title
-----------------
To Establish the Traditional Chinese Medicine Based Intelligent Personal Health Care System

Conditions
-----------------
Traditional Chinese Medicine Body Constitution

Intervention / Treatment
-----------------
* Other: CCMQ questionnaire


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Aged over 18 and under 85. Participants agreed to join the trial by fully understanding the purpose of the study and the entire trial process and then signed an informed consent. Able to fill out online questionnaire with any electronic device in person or under assistance Exclusion Criteria: Age of subjects was under 18 or more than 85 years old. Participants who do not meet the above criteria Subjects were not willing sign the informed consent.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 85 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| All subjects<br>Subjects who filled out our modified CCMQ questionnaire | Other: CCMQ questionnaire<br>* Test subjects were required to fill out our modified CCMQ (Constitution in Chinese Medicine Questionnaire) Questionnaire.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Constitution in Chinese Medicine Questionnaire(CCMQ)_modified version | Based on the analysis, we have identified nine different types of Traditional Chinese Medicine constitutions. | On the 1 day of receipt | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Base Data Questionnaire | Included collection of basic data (age, BMI, gender, place of residence, education level, smoking status, alcohol drinking, betel nut chewing, exercise frequency, work shift jobs and bedtime), disease status. | On the 1 day of receipt |
In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors

Study Overview
=================
Brief Summary
-----------------
The investigators plan to analyze the data of patients with gastric cancer (GC) consecutively hospitalized in Ruijin Hospital, a large tertiary center in China, comprehensively describe the characteristics of GC patients ≥65 years, and assesse their in-hospital outcomes regarding duration, fee, and death. Factors associated with the in-hospital outcomes will be further comprehensively explored.

Official Title
-----------------
In-hospital Outcomes of Older Patients With Gastric Cancer and Their Risk Factors: Large Comprehensive Institution-based Study

Conditions
-----------------
Gastric Cancer

Intervention / Treatment
-----------------
* Other: Surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Older gastric cancer (GC) patients With primary malignancies of the stomach (International Classification of Diseases for Oncology, Third Edition [ICD-O-3] topology code: C16) ≥65 years Exclusion Criteria: With benign, premalignant, or in situ tumors With cancers originating from non-stomach sites

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Geriatric gastric cancer patients<br> | Other: Surgery<br>* We referr to resection as that performed in our hospital, and history of major abdominal surgery as interventional surgical procedures in the abdomen with therapeutic intent (e.g., resection) prior to the first hospitalization in our hospital.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Mortality during first and all hospitalizations | Up to 1 month | 
| Cost | Costs during first and all hospitalizations | Up to 1 month | 
| Duration of stay | Duration of stay during first and all hospitalizations | Up to 1 month |
A Pilot Study of SPG Block for PTSD

Study Overview
=================
Brief Summary
-----------------
Some patients with Post Traumatic Stress Disorder (PTSD) respond only partially to medication. This study is a pilot study investigating whether blocking the SPG helps reduce the symptoms of PTSD. This study does not involve treatment with medications. It is a proof of principal study.

Detailed Description
-----------------
The sphenopalatine ganglion (SPG) is a collection of neurons involved in autonomic regulation (which refers to bodily processes that are automatic like heart rate and blood pressure). Blocking the SPG is used to treat disorders, such as migraines or cluster headaches (short, severe headaches that occur together). The procedure will be performed by a doctor who specializes in ear, nose throat surgery. The block consists of the injection of a numbing agent (similar to the type used by dentists) to the SPG. After the SPG block, we will follow patients for 8 weeks to see how they feel.

Official Title
-----------------
A Feasibility Study of a Sphenopalatine Ganglion (SPG) Block for Post Traumatic Stress Disorder (PTSD)

Conditions
-----------------
Post Traumatic Stress Disorder

Intervention / Treatment
-----------------
* Other: Sphenopalatine ganglion block


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Participants with a principal diagnosis of PTSD on stable dose of psychiatric medication or in stable psychotherapy for at least 3 months, who experience residual symptoms. Participants who understand all study procedures and can undergo informed consent Exclusion Criteria: Participants with a medical disorder, for whom study participation could be deleterious (neurologic, cardiac, renal or infectious disease) Pregnant or breast feeding participants Participants who are on an anticoagulant, such as warfarin, or otherwise have a medical condition that increases bleeding risk

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Active SPG block<br>The block will be performed using a topical aerosolized nasal spray followed by the administration of a local anesthetic. | Other: Sphenopalatine ganglion block<br>* The block is performed with a nasoscope and the administration of a local anesthetic.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| feasibility: number of participants completing the 8-week study | feasibility: number of participants completing the 8-week study | 8 weeks | 
| tolerability: number of adverse events | tolerability: number of adverse events | 8 weeks |
Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Study Overview
=================
Brief Summary
-----------------
This is a mono-center observational ambispective study in which patients with cardiac amyloidosis evaluated at our institution will be enrolled. The primary aim is to investigate echocardiographic findings, particularly using advanced echocardiographic techniques, such as two- and three-dimensional speckle-tracking analysis, that may be helpful in the differential diagnosis between cardiac amyloidosis and other cardiomyopathies with hypertrophic phenotype. Secondary aims are: 1) to evaluate the reversibility of myocardial damage, assessed by echocardiography, in response to a newly available specific treatment for patients with transthyretin-related cardiac amyloidosis (tafamidis ) and its correlation with the clinical response 2) to investigate potential novel echocardiographic predictors of adverse cardiovascular outcomes.

Official Title
-----------------
Echocardiographic Characterization of Cardiac Amyloidosis: an Observational Study

Conditions
-----------------
Cardiac Amyloidosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with cardiac amyloidosis, defined according to the recommendation provided by the working group of the european society of cardiology, with clinical, electrocardiographic ed echocardiographic data at our institution and with at least one follow-up visit. Exclusion Criteria: missing data decline to the study participation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in echocardiographic parameters (in patients receiving or not specific treatment) | variation in global longitudinal strain, diastolic parameters and degree of ventricular hypertrophy | 6 months | 
| cardiovascular outcomes | composite endpoint of death and heart failure hospitalization | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| major cardiac arrhythmias | bradyarrhythmia, new-onset atrial fibrillation, ventricular tachycardia | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
echocardiography, left ventricle
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.

Official Title
-----------------
Population Pharmacokinetic of Piperacillin/Tazobactam in Maternal and Neonatal Populations With High Risk for EOS

Conditions
-----------------
Early-Onset Neonatal Sepsis

Intervention / Treatment
-----------------
* Drug: Piperacillin Sodium and Tazobactam Sodium for Injection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients over 18 years old; Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO； Patients and their families are fully aware of the research content and sign the informed consent form. Exclusion Criteria: Intolerance or serious adverse reactions to antibiotic use; Patients who stopped using PIP/TAZO more than 24 hours before delivery; Receiving other systemic trial drugs; There are other factors that the researchers think are not suitable for inclusion

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Piperacillin Sodium and Tazobactam Sodium for Injection|Piperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Clearance (L/h) of piperacillin/tazobactam | The mean population pharmacokintic parameter as well as its interindividual variability | Through study completion, an average of 20 days. | 
| Volume of Distribution (L) of piperacillin/tazobactam | The mean population pharmacokintic parameter as well as its interindividual variability | Through study completion, an average of 20 days. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| PD target attainment | PD target is defined as the time of free drug concentration beyond MIC during the dose interval | Through study completion, an average of 20 days. | 
| Adverse events | Drug-related adverse events and serious adverse events during the study. | Through study completion, an average of 20 days. |
COVID-19 Pneumonia and Gut Inflammation

Study Overview
=================
Brief Summary
-----------------
The primary objective of our study was to evaluate the efficacy of a mix of three probiotic strains (Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302, and Lactobacillus acidophilus LA 201; Lactibiane Iki®) in the reduction in fecal calprotectin in patients with COVID-19 pneumonia, compared to a control group. The secondary aim was to evaluate the reduction in oxygen support and length of hospital stay in patients taking the probiotic mix.

Official Title
-----------------
COVID-19 Pneumonia and Gut Inflammation: The Role of a Mix of Three Probiotic Strains in Reducing Inflammatory Markers and Need for Oxygen Support

Conditions
-----------------
Inflammation

Intervention / Treatment
-----------------
* Dietary Supplement: probiotics
* Other: standard therapy


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients admitted to our hospital for SARS-CoV-2 infection with respiratory and/or gastrointestinal symptomsandradiological imaging (chest X-ray/CT with/without contrast) of interstitial pneumonia. Patients with mild COVID-19 disease (requiring oxygen support with 2L or 4L nasal cannula or Ventimask 28-35-40% to reach a SpO2-target of 95%) Exclusion Criteria: patients on antibiotic therapy or patients who had taken antibiotics in the previous month; patients with IBD,IBS,or infectious colitis of non-COVID-19 bacterial and/or viral etiology; patients with colonic neoplasia (first to last stage); patients who had undergone colon surgery; patients with severe hepatopathy, nephropathy, heart disease or terminal oncological disease; pregnant women; and patients in circulatory shock and under positive pressure support on admission to hospital.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: probiotic +<br> | Dietary Supplement: probiotics<br>* supplementation with Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201+ standard theraph for sars-cov-2<br>|
| Active Comparator: standard therapy<br> | Other: standard therapy<br>* standard therapy for sars-cov-2<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| efficacy of probiotics in reducing calprotectin and CRP | evaluate the efficacy of a mix of three probiotic strains (Bifidobacterium lactis LA 304, Lactobacillus salivarius LA 302,andLactobacillus acidophilus LA 201) in reducing fecal calprotectin and CRP in patients with COVID-19 pneumonia | 10 days |
Midodrine Effect on the Mortality Rates in Septic Shock Patients

Study Overview
=================
Brief Summary
-----------------
Assessing the safety and efficacy of the adjunctive use of midodrine as a vasopressor in septic shock patients by measuring the difference in the mortality rates between control and intervention groups.

Official Title
-----------------
Clinical Study Evaluating the Efficacy and Safety of Adjunctive Use of Midodrine in Septic Shock Patients

Conditions
-----------------
Septic Shock

Intervention / Treatment
-----------------
* Drug: Midodrine Oral Tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult aged 18 years or older diagnosed with septic shock. Hypotensive and require IV vasopressor for more than 24 hours. Exclusion Criteria: Hypovolemic shock. Severe organic heart disease (ejection fraction <30 percent). Bradycardia (HR<50 b/m). Chronic kidney disease (serum creatinine >2mg/dl). Thyrotoxicosis. Pheochromocytoma. Known allergy to midodrine. Unable to administer an oral medication.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Placebo Comparator: Control<br>Will receive IV vasopressor infusion only | Drug: Midodrine Oral Tablet<br>* Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.<br>|
| Active Comparator: Midodrine<br>Will receive oral midodrine 10 mg/ 8 hours in addition to IV vasopressor infusion till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours). | Drug: Midodrine Oral Tablet<br>* Patients will receive standard treatment in accordance to surviving sepsis campaign guidelines plus oral midodrine 10 mg/ 8 hours till the end of treatment (subject remaining vasopressor-free for 24 consecutive hours) or death.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality rates | The primary outcome is measuring the difference in ICU mortality rates between control and intervention group. | Time Frame: Starting from date of randomization till shock reversal or date of death from any cause, whichever came first,assessed up to 30 days |
Variability of Healthy People and People After Stroke Results in the Box and Block Test

Study Overview
=================
Brief Summary
-----------------
Main aim of the study is to find out how many attempts of each subtest in the Box and Block Test should be done in clinical practice during testing people after stroke who are 20-64 years old.

Official Title
-----------------
Variability of Healthy People and People After Stroke Results in the Box and Block Test

Conditions
-----------------
Motor Activity

Intervention / Treatment
-----------------
* Diagnostic Test: Box and Block Test


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: people after stroke 20 - 64 years old signed Informed consent for probation with inclusion to research and Consent to the collection and processing of personal data during the study at the General University Hospital in Prague ability to sit independently for 15 minutes ability to grasp and move at least one 25 mm wide cube placed on a table using the dominant and then the non-dominant upper limb across the test partition ability to perform a simple task following verbal instructions retained ability to understand - according to psychological examination completion of testing during hospitalization in the Beroun Rehabilitation Hospital Exclusion Criteria: severe hearing impairment not corrected by a hearing aid severe visual impairment not corrected by glasses severe comprehension impairment other reasons not allowing the completion of the entire testing using the Box and Block Test

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 64 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| People after stroke<br>Czech people after stroke, aged 20 - 64 years | Diagnostic Test: Box and Block Test<br>* 3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test<br>* Other names: questionnaire;|
| Healthy population<br>Czech healthy people, aged 20 - 64 years | Diagnostic Test: Box and Block Test<br>* 3 attempts of each subtest of the Box and Block Test performed according to the Czech Extended Version of Manual for the Box and Block Test<br>* Other names: questionnaire;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| results from the Box and Block Test | number of transported blocks | 30 minutes | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Box and Block Test, Stroke, Czech Extended Version of Manual for the Box and Block Test